
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Eikon Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.0001 par value per share

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)
-

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Innovation Endeavors III LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

CAYMAN ISLANDS

Number of Shares Beneficially

5

Sole Voting Power

0.00

Owned by Each Reporting Person With: 6 Shared Voting Power
2,723,226.00
Sole Dispositive Power
7
0.00
Shared Dispositive Power
8
2,723,226.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
2,723,226.00
10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)
5.0 %
12 Type of Reporting Person (See Instructions)
PN

SCHEDULE 13G

CUSIP No.

1 Names of Reporting Persons
Innovation Endeavors III GP, LLC
Check the appropriate box if a member of a Group (see instructions)

2 (a)
 (b)

3 Sec Use Only
4 Citizenship or Place of Organization

CAYMAN ISLANDS
Sole Voting Power
5
0.00
Number of Shares Beneficially Owned by Each Reporting Person With: 6 Shared Voting Power
2,723,226.00
Sole Dispositive Power
7
0.00
Shared Dispositive Power
8
2,723,226.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person
2,723,226.00
10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11 Percent of class represented by amount in row (9)
5.0 %

12 Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Innovation Endeavors IV LP

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by
Each

498,474.00

Reporting
Person

Sole Dispositive Power

7

0.00

With:

Shared Dispositive

8

Power

498,474.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

498,474.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.9 %

Type of Reporting Person (See Instructions)

12

PN

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Innovation Endeavors IV GP, LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3 Sec Use Only
Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power
498,474.00

Sole Dispositive Power

7 0.00

8 Shared Dispositive Power

498,474.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9 498,474.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11 0.9 %

Type of Reporting Person (See Instructions)

12 OO

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1 Innovation Endeavors ET SPV LP

Check the appropriate box if a member of a Group (see instructions)

2 (a)

(b)

3 Sec Use Only

Citizenship or Place of Organization

4 DELAWARE

Sole Voting Power

5 0.00

Number of Shares Beneficially Owned by Each Reporting Person With:

6 Shared Voting Power
147,819.00

Sole Dispositive Power

7 0.00

8 Shared Dispositive Power

147,819.00

9 Aggregate Amount Beneficially Owned by Each Reporting Person

147,819.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.3 %

Type of Reporting Person (See Instructions)

12

PN

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

Innovation Endeavors ET SPV GP LLC

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

Beneficially
Owned by

147,819.00

Each
Reporting

Sole Dispositive Power

7

Person

0.00

With:

Shared Dispositive

8

Power

147,819.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

147,819.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

0.3 %

Type of Reporting Person (See Instructions)

12

OO

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Eikon Therapeutics, Inc.

Address of issuer's principal executive offices:

(b)

230 Harriet Tubman Way, Millbrae, CA, 94030.

Item 2.

Name of person filing:

(a)

The names of the persons filing this report (collectively, the "Reporting Persons") are: Innovation Endeavors III LP ("IE III LP") Innovation Endeavors III GP, LLC ("IE III GP") Innovation Endeavors IV LP ("IE IV LP") Innovation Endeavors IV GP, LLC ("IE IV GP") Innovation Endeavors ET SPV LP ("IE ET SPV") Innovation Endeavors ET SPV GP LLC ("IE ET GP") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

(b)

Address or principal business office or, if none, residence:

1845 El Camino Real, Palo Alto, CA 94306

Citizenship:

(c)

IE III LP Cayman Islands IE III GP Cayman Islands IE IV LP Delaware IE IV GP Delaware IE ET SPV Delaware IE ET GP Delaware

(d)

Title of class of securities:

Common Stock, \$0.0001 par value per share

(e)

CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
- (k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

Amount beneficially owned:

(a)

Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 2,723,226 shares of common stock directly held by IE III LP; (ii) 498,474 shares of common stock directly held by IE IV LP; and (iii) 147,819 shares of common stock directly held by IE ET SPV. IE III GP is the general partner of IE III LP and shares voting and investment authority over the shares held by IE III LP. IE IV GP is the general partner of IE IV LP and shares voting and investment authority over the shares held by IE IV LP. IE ET GP is the general partner of IE ET SPV and shares voting and investment authority over the shares held by IE ET SPV.

Percent of class:

(b)

Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference. The percentage set forth in each row 11 is based upon 54,138,555 shares of common stock outstanding as of March 17, 2026, as reported in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on March 30, 2026. Collectively, the Reporting Persons beneficially owned an aggregate of 6.2% of the outstanding common stock of the Issuer as of March 31, 2026. %

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

(ii) Shared power to vote or to direct the vote:

Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

(iii) Sole power to dispose or to direct the disposition of:

Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

(iv) Shared power to dispose or to direct the disposition of:

Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of March 31, 2026 and is incorporated by reference.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.
Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable

Item 8. Identification and Classification of Members of the Group.
Not Applicable

Item 9. Notice of Dissolution of Group.
Not Applicable

Item 10. Certifications:
Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Innovation Endeavors III LP

Signature: /s/ Dror Berman

Name/Title: By Innovation Endeavors III GP, LLC, its General Partner, By Dror Berman, Managing Member

Date: 05/15/2026

Innovation Endeavors III GP, LLC

Signature: /s/ Dror Berman

Name/Title: By Dror Berman, Managing Member

Date: 05/15/2026

Innovation Endeavors IV LP

Signature: /s/ Dror Berman

Name/Title: By Innovation Endeavors IV GP, LLC, its General Partner, By Dror Berman, Managing Member

Date: 05/15/2026

Innovation Endeavors IV GP, LLC

Signature: /s/ Dror Berman

Name/Title: By Dror Berman, Managing Member

Date: 05/15/2026

Innovation Endeavors ET SPV LP

Signature: /s/ Dror Berman

By Innovation Endeavors ET SPV GP LLC, its

Name/Title: General Partner, By Dror Berman, Managing
Member

Date: 05/15/2026

Innovation Endeavors ET SPV GP LLC

Signature: /s/ Dror Berman

Name/Title: By Dror Berman, Managing Member

Date: 05/15/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

JOINT FILING STATEMENT

We, the undersigned, hereby express our agreement that the attached statement on Schedule 13G relating to the common stock of Eikon Therapeutics, Inc. is filed on behalf of each of us.

Dated: May 15, 2026

Innovation Endeavors III LP

By: Innovation Endeavors III GP, LLC
Its: General Partner

By: /s/ Dror Berman
Name: Dror Berman
Title: Managing Member

Innovation Endeavors III GP, LLC

By: /s/ Dror Berman
Name: Dror Berman
Title: Managing Member

Innovation Endeavors IV LP

By: Innovation Endeavors IV GP, LLC
Its: General Partner

By: /s/ Dror Berman
Name: Dror Berman
Title: Managing Member

Innovation Endeavors IV GP, LLC

By: /s/ Dror Berman
Name: Dror Berman
Title: Managing Member

Innovation Endeavors ET SPV LP

By: Innovation Endeavors ET SPV GP LLC
Its: General Partner

By: /s/ Dror Berman
Name: Dror Berman
Title: Managing Member

Innovation Endeavors ET SPV GP LLC

By: /s/ Dror Berman
Name: Dror Berman
Title: Managing Member